Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
about
Leucoreduction of blood components: an effective way to increase blood safety?Transfusion medicine problems and solutions for the pediatric hematologist/oncologistPrevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?Transfusion-transmitted infectionsTransfusion-Transmitted InfectionsSeroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa.Prevention of maternal cytomegalovirus infection: current status and future prospects.Human Cytomegalovirus (HCMV) - Revised.What every physician should know about transfusion reactions.Alternative blood products and clinical needs in transfusion medicineSystematic Evaluation of Different Nucleic Acid Amplification Assays for Cytomegalovirus Detection: Feasibility of Blood Donor Screening.Seroprevalence of Cytomegalovirus among Voluntary Blood Donors.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Transfusion strategies in patients undergoing stem-cell transplantation.A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States.Supportive care in severe and very severe aplastic anemia.Safety of the blood supply.Adverse effects of transfusion.Transfusion-transmitted CMV infection - current knowledge and future perspectives.Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis.Survey of Institutional Policies for Provision of "CMV-Safe" Blood in Ontario.Cytomegalovirus in Australian blood donors: seroepidemiology and seronegative red blood cell component inventories.Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy.Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.Cytomegalovirus and Epstein-Barr virus reactivation in the intensive care unit.The effects of red cell transfusion donor age on nosocomial infection among trauma patients.Infectivity of blood products containing cytomegalovirus DNA: results of a lookback study in nonimmunocompromised patients.Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components.Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors.New insights for preventing transfusion-transmitted cytomegalovirus and other white blood cell-associated viral infections.Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil.High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.Cytomegalovirus-safe blood: the unclear effect of sickle hemoglobin.Comparison of the two fully automated anti-HCMV IgG assays: Abbott Architect CMV IgG assay and Biotest anti-HCMV recombinant IgG ELISA.The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients.Transfusion support in preterm neonates <1500 g and/or <32 weeks in a tertiary care center: A descriptive study.Optimal prevention of transfusion-transmitted cytomegalovirus (TTCMV) infection by modern leukocyte reduction alone: CMV sero/antibody-negative donors needed only for leukocyte products.
P2860
Q26771857-29BA5BDE-FB61-4C61-9BF4-D2EC6DD80DCBQ26851995-1A6D4DEE-561B-4EAE-9ED1-4A38F3380877Q27005922-EE18E2D7-5985-4593-A6D5-2492F5C39A5AQ27480405-3DBE99C8-0681-4F44-9AE6-EA1C0CA517D0Q29571219-30CE06DD-DF25-46E9-8865-A012634C540FQ33360459-6BC6BCD2-D1DF-4F47-8EE4-DA138DA2E3BFQ34272089-ADF33FEF-272A-421B-82FC-CC9BBDAEBEF1Q34625453-FFEC2844-151E-45BD-91E4-AD9432C7C77CQ35878583-87756231-7417-427F-8663-89BAC5A18F2BQ35915095-2AC4A3E5-38F3-4A7E-8D0D-FE7A574BDE16Q36066896-B95A6BDF-3522-4653-B401-44CA9A8B7F83Q37038937-F28088CA-90D4-4338-99EC-701146BAF280Q37680941-480D65F2-6B2A-4DBC-952C-A50C145DAA84Q37865548-C5800B90-24F6-4234-8CA6-F10E92C58334Q38052141-EC0C3A09-A687-4A09-8352-02CCBCC7F2B1Q38064773-DD5A7921-39C9-45CF-B500-7322F0DCF9D5Q38287590-FB0FE411-A8BC-413A-B7BD-947129186F6AQ38287593-561711F9-373C-4423-9661-406FDD166099Q38667640-617DD96C-8457-4D8D-AC0F-4C4D956045D2Q38716452-B69CD8B8-EF82-4AE9-AE67-06E50672DF72Q38826565-B0EF099A-4B3C-43A9-966C-97ABF4BF6BF7Q38917178-E5F8F06F-4D3A-4D5F-A97A-29C61899B79CQ39849819-B6827B03-10AE-4688-8794-8477011B30A7Q40044400-403E44B6-7394-46C9-892F-DC0A5A33E668Q40096110-63430E57-2F2E-415E-891D-3409C0662856Q40129640-BC067523-2504-496D-AA91-FF970754F3B6Q40261427-AC5A6A6D-6C24-4D5B-8C11-EA084878ED66Q40611312-E1BFC9FE-AF3E-4693-8E8F-26B4AB7EA4EEQ41100504-7195D239-72E8-4944-B02D-EAB0979293CDQ41138332-DD83D2A5-D61D-46FB-B98A-970255C5C3DEQ42275032-605A3E88-072D-4D11-8360-4715B226F039Q43956762-3EF1882C-17FF-4BEC-B8DF-4FD11119FEC3Q45349530-85D2C636-3B80-401B-95F4-0A9093D97828Q46933800-44B7778C-AD6B-450D-BAD7-EB7D0D3E17ABQ50205456-96809305-C887-4384-BDEB-1469354226B1Q51074281-0A4F23B3-00EA-4808-8B94-598987BCA8D5Q51818445-ED28796A-5E09-4A9F-BF6B-2A55FBA98A72Q52643860-423EA996-2C8C-4FF2-AE31-4E4ECDD8F381Q54543005-E5B9F9AE-589F-4686-8569-45A47F44C555
P2860
Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Is white blood cell reduction ...... literature and meta-analysis.
@ast
Is white blood cell reduction ...... literature and meta-analysis.
@en
type
label
Is white blood cell reduction ...... literature and meta-analysis.
@ast
Is white blood cell reduction ...... literature and meta-analysis.
@en
prefLabel
Is white blood cell reduction ...... literature and meta-analysis.
@ast
Is white blood cell reduction ...... literature and meta-analysis.
@en
P1476
Is white blood cell reduction ...... literature and meta-analysis.
@en
P2093
Eleftherios C Vamvakas
P304
P356
10.1016/J.TMRV.2005.02.002
P577
2005-07-01T00:00:00Z